医学
冠状动脉疾病
疾病
内科学
心脏病学
人口
多基因风险评分
弗雷明翰风险评分
相对风险
风险评估
绝对风险降低
动脉疾病
动脉
冠状动脉粥样硬化
冠心病
冠心病
风险因素
遗传变异
托换
流行病学
全基因组关联研究
动脉粥样硬化性心血管疾病
终身风险
作者
Heribert Schunkert,Pradeep Natarajan,Nilesh J. Samani
标识
DOI:10.1056/nejmra2405153
摘要
Investigations of the genetic basis of coronary artery disease have led to advances in mechanistic insights, therapeutics, prevention, and risk prediction. Indeed, most contemporary medicines for coronary artery disease target pathways that promote atherosclerosis due to underpinning genetic mechanisms. Monogenic causes of coronary artery disease occur in approximately 1 out of 250 people and mostly result in massively elevated lipid levels. At the population level, hundreds of common variants with small effect sizes have even greater influence. They can be combined in polygenic risk scores that depict genetic risk in a person relative to the average in the general population. The risk among persons in the highest 5% is 3 to 5 times that among persons with an average score; relative risk derived from the polygenic risk score can be used to multiply the absolute risk derived from a clinical risk score. Key questions remain regarding the clinical value, cost-effectiveness, and implementation strategies required to integrate coronary artery disease polygenic risk scores into clinical practice.
科研通智能强力驱动
Strongly Powered by AbleSci AI